Wells Fargo & Company Femasys Inc Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.75 - $2.22 $25 - $75	34 Added 30.91%	144 $0
Q4 2023 Feb 09, 2024	BUY	$0.76 - $3.89 $12 - $66	17 Added 18.28%	110 $0
Q3 2023 Nov 13, 2023	BUY	$0.31 - $2.98 $4 - $47	16 Added 20.78%	93 $0
Q2 2023 Aug 15, 2023	BUY	$0.51 - $1.26 $5 - $13	11 Added 16.67%	77 $0
Q1 2023 May 12, 2023	BUY	$0.85 - $1.29 $0 - $1	1 Added 1.54%	66 $0
Q4 2022 Feb 13, 2023	BUY	$0.83 - $1.41 $0 - $1	1 Added 1.56%	65 $0
Q3 2022 Nov 14, 2022	SELL	$1.13 - $2.54 $1,078 - $2,423	-954 Reduced 93.71%	64 $0
Q2 2022 Aug 12, 2022	BUY	$1.3 - $2.76 $1,301 - $2,762	1,001 Added 5888.24%	1,018 $2,000
Q3 2021 Nov 15, 2021	BUY	$6.52 - $8.5 $110 - $144	17 New	17 $0

2.34M

Ticker FEMY
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 11,813,600
Market Cap $18.9M
Description
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.